How much cash does Enliven Therapeutics generate?

Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.

What is Enliven Therapeutics's free cash flow?

After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.

Where does Enliven Therapeutics's cash flow data come from?

Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Enliven Therapeutics ELVN Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$103.69M-16.5%	-$89.02M-24.4%	-$71.58M-90.1%	-$37.66M+26.7%
Depreciation and amortization	$263K-17.0%	$317K+6.7%	$297K+38.1%	$215K+117%
Stock-based compensation	$34.02M+68.6%	$20.17M+56.2%	$12.91M+305%	$3.19M-17.0%
Gain (loss) on sale of assets	-$106K-864%	-$11K—	——	$35M—
Change in accounts payable	$817K—	——	-$2.25M-647%	$411K—
Change in accrued liabilities	——	-$248K-103%	$7.66M+375%	$1.61M+310%
Change in operating lease liabilities	-$337K-0.6%	-$335K-8.1%	-$310K—	——
Net cash from operating activities	-$70.3M+3.9%	-$73.19M-19.5%	-$61.27M-91.0%	-$32.08M+31.4%
Capital expenditures	——	$44K-70.5%	$149K-75.7%	$612K—
Proceeds from sale of property, plant and equipment	$213K—	$0—	——	——
Net cash from investing activities	-$186.22M—	——	——	-$612K+62.5%
Proceeds from issuance of common stock	$2.3M—	$0—	——	$0-100%
Net cash from financing activities	$219.24M+64.6%	$133.17M—	——	-$1.8M-104%
Net increase (decrease) in cash	——	$23.98M—	——	-$34.49M—
Accretion (Amortization) of Discounts and Premiums, Investments	——	-$424K-109%	$4.6M—	$0+100%
Depreciation	$263K-17.0%	$317K+6.7%	$297K+38.1%	$215K+117%
Gain/(loss) on dispositions, net	-$106K-864%	-$11K—	——	——
Accrued expenses and other liabilities	——	-$248K-103%	$7.66M+375%	$1.61M+310%
Operating lease liabilities	-$337K-0.6%	-$335K-8.1%	-$310K—	——
Prepaid expenses and other current assets	——	——	——	$1.59M—
Non Cash Lease Expense	$353K+10.3%	$320K+4.6%	$306K—	——
Proceeds from disposals of property, plant and equipment	$213K—	$0—	——	——
Proceeds From Issuance Of Common Stock Under Sales Agreement Net Of Issuance Costs	$0-100%	$39.19M—	$0—	——
Increase Decrease In Operating Lease Liability	-$337K-0.6%	-$335K-8.1%	-$310K—	——
Operating Lease Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities	——	$0—	——	——
Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets	——	$0-100%	$76K—	——
Free cash flow	-$70.46M+3.8%	-$73.24M-19.2%	-$61.42M-87.9%	-$32.69M+30.1%
Free cash flow	-$70.46M+3.8%	-$73.24M-19.2%	-$61.42M-87.9%	-$32.69M+30.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Enliven Therapeutics generate?: Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
What is Enliven Therapeutics's free cash flow?: After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
Where does Enliven Therapeutics's cash flow data come from?: Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.